Advertisement
Home Tags Chemotherapy

Tag: Chemotherapy

Risk of cardiotoxicity is higher for patients receiving trastuzumab and/or anthracyclines for the treatment of breast cancer

Cardiac Monitoring Needed for High-Risk Breast Cancer Patients

0
Trastuzumab, certain chemo treatments increase patient risk of heart failure
For patients with previously treated advanced gastric cancer or gastro-esophageal junction cancer

Pembrolizumab Not Better Than PTX for Advanced Gastric Cancer

0
Survival no better with second-line pembrolizumab than paclitaxel for gastric, gastro-esophageal cancer
Overall survival is increased for African-American men with metastatic castration resistant prostate cancer versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen

ASCO: Overall Survival Up for African-American Men With mCRPC

0
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP-containing regimen
The oxaliplatin

ASCO: mFOLFIRINOX Improves Survival in Pancreatic Cancer

0
And, pre-op chemoradiotherapy linked to longer overall survival than immediate surgery
BRCA1/BRCA2 germline mutation carriers with pancreatic ductal adenocarcinoma have worse survival after resection

Worse Survival for BRCA Germline Mutation Carriers in Pancreatic CA

0
For BRCA germline mutation carriers, better survival seen with platinum-based chemotherapy
Short-term mortality is similar among patients with hematologic cancer who receive chemotherapy while in the intensive care unit versus those who do not

ICU Mortality Similar for Patients With Hematologic CA ± Chemo

0
However, patients with hematologic cancer receiving chemotherapy have longer ICU, hospital stays
Childhood cancer survivors frequently have clinical abnormalities attributable to peripheral neuropathy

Peripheral Neuropathy Common in Childhood Cancer Survivors

0
Long-term neurotoxicity was more frequently seen with cisplatin than with vinca alkaloids
For patients with locally advanced esophageal cancer

Nodal Response to Pre-Op Tx Tied to Survival in Esophageal Cancer

0
Survival benefit of nodal response maintained among patients with nodal, but not primary response
Gemcitabine and cisplatin plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

0
One-year overall survival of 61 percent for gemcitabine and cisplatin plus ipilimumab
Underlying leukemia

Leukemia, and Its Treatment, May Pose Neurocognitive Risks

0
Cerebrospinal fluid biomarkers may identify those at greater risk for poor neuro-related outcomes